Sponsor Oversight Under ICH E6(R3): What You Keep
ICH E6(R3) lets a sponsor transfer any trial activity and keeps the responsibility with the sponsor. What oversight has to look like, and where it breaks.
QC Record Review: What 21 CFR 211.194 Asks For
What 21 CFR 211.194 requires in a QC lab record, what the second-person review confirms, and where worksheets stop matching the approved method.
Device Supplier Quality Under QMSR: Clause 7.4 and PPAP
What ISO 13485 clause 7.4 requires under the QMSR, where PPAP fits, and where device supplier packages contradict themselves.
Supplier Qualification Under GMP: What the File Has to Prove
What a supplier qualification file has to prove under 21 CFR 211.84, ICH Q7, ICH Q10 and EU GMP Chapters 5 and 7, and where supplier records stop agreeing.
How to Read an FDA Warning Letter Against Your Own Procedures
FDA publishes what it cited at other sites. A five-step way to test a published 483 or warning letter against your own procedures.
QMSR Inspections: What FDA Reads Now in Device Records
The QMSR took effect on February 2, 2026. FDA device inspections now open management review, internal audit and supplier audit records. Here is where device records stop agreeing.Quality and Regulatory Intelligence Platforms: The 2026 Landscape
Six categories of quality and regulatory intelligence platforms for pharma, biotech and medical device, with named examples and where each one fits.Why drugs fail FDA review on quality, not science
FDA released 202 Complete Response Letters in July 2025. Manufacturing and quality deficiencies appeared in 74% of them. The clinical data was rarely the problem.Deviation investigation cost and CAPA closure benchmarks: what the numbers actually say
Same 21 CFR rules at four people as at forty. A clinical-stage biotech carries enterprise regulatory requirements on startup resources, which is why the ROI math for AI in QMS looks nothing like the enterprise pharma case.